← Leaderboards
Bryce C Chackerian
University Of New Mexico Health Scis Ctr
$17,300,500
Attributed
$19,919,512
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,919,512 · 16
By mechanism
R01$10,444,391 · 6
U19$5,186,709 · 4
UG3$1,572,708 · 1
RC2$1,000,000 · 1
UH3$849,872 · 1
T32$608,116 · 1
Top collaborators
- Daniel Lingwood9 shared
- Judy Lin Cannon1 shared
Most similar at University Of New Mexico Health Scis Ctr
Same institution · by research overlap
- Kathryn M. Frietze$1,554,224
- Andzoa Jamus$75,468
Others in their field
Top investigators on “Virus-Like Particle”
- Rama Rao Amara · Emory University$24,419,800
- Richard J. Kuhn · Purdue University$14,381,988
- Rolando Herrero · Fundacion Inciensa$14,003,389
- Yoshihiro Kawaoka · University Of Wisconsin Madison$12,082,921
- Sang-Moo Kang · Emory University$11,629,067
- James M Binley · Weill Medical College Of Cornell Univ$11,594,721
Research focus
Virus-Like ParticleVaccinesAntibodiesAntigensEpitopesPeptidesBaseImmunogenicityImmunogenicSurfaceTechnologyB-LymphocytesVaccine CandidateImmune ResponseAntibody ResponseVaccinationResponseEngineeringImmunizationInfectionViralRna PhagesBacteriophagesNeutralizing Antibody
Grant awards (47)
Bacteriophage virus-like particle vaccines for fentanyl and heroin overdose$849,872
UH3 · FY2025 · DA · contact PI
Initiative to Maximize Student Diversity at the University of New Mexico Health Sciences Center 2021$608,116
T32 · FY2025 · GM · contact PI
Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein$592,698
R01 · FY2025 · AI · contact PI
Project 2 - VLP-based vaccines displaying PorB peptides that induce functional antibodies (CIIG)$507,831
U19 · FY2025 · AI · contact PI
Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein$611,029
R01 · FY2024 · AI · contact PI
Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein$637,784
R01 · FY2023 · AI · contact PI
Peptide-VLP Vaccines$310,483
U19 · FY2023 · AI · contact PI
Innate-like BCR activity as a template for universal vaccination against influenza virus$546,158
R01 · FY2022 · AI
Peptide-VLP Vaccines$217,467
U19 · FY2022 · AI · contact PI
Bacteriophage virus-like particle vaccines for fentanyl and heroin overdose$1,572,708
UG3 · FY2021 · DA · contact PI
Innate-like BCR activity as a template for universal vaccination against influenza virus$511,894
R01 · FY2021 · AI
Peptide-VLP Vaccines$285,212
U19 · FY2021 · AI · contact PI
CDRH3-independent B cell stimulation to selectively expand VRC01 lineages from a fully humanized immunoglobulin repertoire$535,368
R01 · FY2020 · AI
A nanoparticle-based vaccine targeting PCSK9$513,123
R01 · FY2020 · HL · contact PI
Innate-like BCR activity as a template for universal vaccination against influenza virus$483,855
R01 · FY2020 · AI
Peptide-VLP Vaccines$274,596
U19 · FY2020 · AI · contact PI
A nanoparticle-based vaccine targeting PCSK9$580,797
R01 · FY2019 · HL · contact PI
Innate-like BCR activity as a template for universal vaccination against influenza virus$543,444
R01 · FY2019 · AI
CDRH3-independent B cell stimulation to selectively expand VRC01 lineages from a fully humanized immunoglobulin repertoire$530,570
R01 · FY2019 · AI
Peptide-VLP Vaccines$287,481
U19 · FY2019 · AI · contact PI
Opioid vaccine development using bacteriophage virus-like particle (VLP) immunogens$251,499
R01 · FY2019 · HL · contact PI
Innate-like BCR activity as a template for universal vaccination against influenza virus$552,569
R01 · FY2018 · AI
CDRH3-independent B cell stimulation to selectively expand VRC01 lineages from a fully humanized immunoglobulin repertoire$450,370
R01 · FY2018 · AI
Discovery and Refinement of Preventive STI Vaccines Targeting Critical Epitopes o$374,906
U19 · FY2018 · AI · contact PI
A nanoparticle-based vaccine targeting PCSK9$347,408
R01 · FY2018 · HL · contact PI
CDRH3-independent B cell stimulation to selectively expand VRC01 lineages from a fully humanized immunoglobulin repertoire$475,680
R01 · FY2017 · AI
A nanoparticle-based vaccine targeting PCSK9$333,545
R01 · FY2017 · HL · contact PI
Discovery and Refinement of Preventive STI Vaccines Targeting Critical Epitopes o$306,520
U19 · FY2017 · AI · contact PI
Discovery and Refinement of Preventive STI Vaccines Targeting Critical Epitopes o$306,131
U19 · FY2016 · AI · contact PI
Discovery and Refinement of Preventive STI Vaccines Targeting Critical Epitopes o$322,749
U19 · FY2015 · AI · contact PI
Discovery and Refinement of Preventive STI Vaccines Targeting Critical Epitopes o$278,951
U19 · FY2014 · AI · contact PI
Vaccines that induce broadly neutralizing antibodies against Human Papillomarviru$390,799
U19 · FY2013 · AI · contact PI
A VLP-based platform for Vaccine Discovery$281,041
R01 · FY2013 · AI · contact PI
Vaccines that induce broadly neutralizing antibodies against Human Papillomarviru$364,605
U19 · FY2012 · AI · contact PI
A VLP-based platform for Vaccine Discovery$298,980
R01 · FY2012 · AI · contact PI
Vaccines that induce broadly neutralizing antibodies against Human Papillomarviru$330,539
U19 · FY2011 · AI · contact PI
A VLP-based platform for Vaccine Discovery$298,980
R01 · FY2011 · AI · contact PI
EVALUATION OF A CCR5 VACCINE FOR HIV INFECTION IN THE SIV/MACAQUE MODEL$143,611
P51 · FY2011 · RR · contact PI
Evaluation of a CCR5 Vaccine for HIV infection in the SIV/Macaque Model$500,000
RC2 · FY2010 · CA · contact PI
Vaccines that induce broadly neutralizing antibodies against Human Papillomarviru$321,241
U19 · FY2010 · AI · contact PI
A VLP-based platform for Vaccine Discovery$300,167
R01 · FY2010 · AI · contact PI
EVALUATION OF A CCR5 VACCINE FOR HIV INFECTION IN THE SIV/MACAQUE MODEL$114,105
P51 · FY2010 · RR · contact PI
Evaluation of a CCR5 Vaccine for HIV infection in the SIV/Macaque Model$500,000
RC2 · FY2009 · CA · contact PI
Vaccines that induce broadly neutralizing antibodies against Human Papillomarviru$307,198
U19 · FY2009 · AI · contact PI
Induction of autoantibodies against CCR5$250,044
R01 · FY2008 · AI · contact PI
Induction of autoantibodies against CCR5$254,888
R01 · FY2007 · AI · contact PI
Induction of autoantibodies against CCR5$262,500
R01 · FY2006 · AI · contact PI